News and Announcements
Inside Healthcare Investing: How KP Rx is Transforming Australia’s Biotech Industry
- Published November 08, 2024 5:04AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Join us in this in-depth interview with Hashan De Silva, Founder of KP Rx, as he shares the journey behind launching a specialist healthcare VC firm. Learn how KP Rx is transforming biotech and medical device investments in Australia and New Zealand by capitalising on key market advantages. Hashan explains the firm’s unique approach, valuation arbitrage, and insights into healthcare investment strategies that have yielded significant success.
Executive Interviews
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
